An essential need exists for microarray-based experimentation and expertise required by investigators of the SPORE. in Prostate Cancer. The SPORE in Prostate Cancer Core Facility for the DNA Array is designed to provide a comprehensive resource to meet this need. There are several critical issues that face investigators using microarrays for high-throughput nucleic acid analysis that this centralized resource will address including: satisfying the need for experienced technical support and specialized equipment; quality control and trouble shooting for critical procedures to maintain consistent and reproducible technique; cost effective, equitable efficient use of shared equipment and supplies; expertise for experiment planning and data analysis; and facilitating interactions between projects and cores in the SPORE. This resource is the most efficient and cost effective means to provide these necessary research components to the multiple investigators in this SPORE that use microarray-based experiments. The overall objective of this core is to provide an efficient, high-quality, centralized DNA array resource supporting projects in this SPORE. The specifics of this core facility are: 1) To provide consultation at all stages of project development and experimentation using microarray techniques; 2) to provide synthesis and labeling of nucleic acid target for microarray experiments; 3) to provide custom array production; 4) to provide microarray hybridization, washing, staining, image analysis and data management services for projects of the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092629-02
Application #
6656475
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-10
Project End
2003-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Han, SoHyun; Stoyanova, Radka; Lee, Hansol et al. (2018) Automation of pattern recognition analysis of dynamic contrast-enhanced MRI data to characterize intratumoral vascular heterogeneity. Magn Reson Med 79:1736-1744
Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245
Kinsella, Netty; Helleman, Jozien; Bruinsma, Sophie et al. (2018) Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 7:83-97
Hieronymus, Haley; Murali, Rajmohan; Tin, Amy et al. (2018) Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7:
Scher, Howard I; Graf, Ryon P; Schreiber, Nicole A et al. (2018) Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncol 4:1179-1186
Bielski, Craig M; Zehir, Ahmet; Penson, Alexander V et al. (2018) Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet 50:1189-1195
Luo, Jun; Attard, Gerhardt; Balk, Steven P et al. (2018) Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol 73:715-723
Settleman, Jeffrey; Sawyers, Charles L; Hunter, Tony (2018) Challenges in validating candidate therapeutic targets in cancer. Elife 7:
Miyazawa, Miki; Subbaramaiah, Kotha; Bhardwaj, Priya et al. (2018) Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. Cancer Prev Res (Phila) 11:215-226
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467

Showing the most recent 10 out of 505 publications